Cell Reports (Jun 2023)

Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation

  • Junlei Zhang,
  • Jinyuan Song,
  • Shima Tang,
  • Yaxing Zhao,
  • Lin Wang,
  • Yandong Luo,
  • Jianghui Tang,
  • Yongtao Ji,
  • Xun Wang,
  • Taohong Li,
  • Hui Zhang,
  • Wei Shao,
  • Jianpeng Sheng,
  • Tingbo Liang,
  • Xueli Bai

Journal volume & issue
Vol. 42, no. 6
p. 112620

Abstract

Read online

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that typically demonstrates resistance to chemotherapy. Tumor-associated macrophages (TAMs) are essential in tumor microenvironment (TME) regulation, including promoting chemoresistance. However, the specific TAM subset and mechanisms behind this promotion remain unclear. We employ multi-omics strategies, including single-cell RNA sequencing (scRNA-seq), transcriptomics, multicolor immunohistochemistry (mIHC), flow cytometry, and metabolomics, to analyze chemotherapy-treated samples from both humans and mice. We identify four major TAM subsets within PDAC, among which proliferating resident macrophages (proliferating rMφs) are strongly associated with poor clinical outcomes. These macrophages are able to survive chemotherapy by producing more deoxycytidine (dC) and fewer dC kinases (dCKs) to decrease the absorption of gemcitabine. Moreover, proliferating rMφs promote fibrosis and immunosuppression in PDAC. Eliminating them in the transgenic mouse model alleviates fibrosis and immunosuppression, thereby re-sensitizing PDAC to chemotherapy. Consequently, targeting proliferating rMφs may become a potential treatment strategy for PDAC to enhance chemotherapy.

Keywords